FDA Panel Shoots Down Oscient Request

Law360, New York (September 13, 2006, 12:00 AM EDT) -- A panel of the U.S. Food and Drug Administration said Tuesday that Oscient Pharmaceuticals Corp. had not proved its Factive drug is safe and effective enough to use for the treatment of acute bacterial sinusitis.

The leading ingredient in Factive, gemifloxacin, is already approved as a seven-day treatment for community-acquired pneumonia and a five-day treatment for certain cases of chronic bronchitis.

Studies have shown a high risk of skin rashes, though, when the drug is used for sinusitis, an inflammation of the sinuses caused by bacterial,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.